Author

Michael J. Kelso

ORCID 0000-0001-7809-6637Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Daniel TillettiD· 2 shared Dylan J. KiltschewskijiD· 2 shared Heather C. MurrayiD· 2 shared Joshua S. BrzozowskiiD· 2 shared Marinella Messina· 2 shared Murray J. CairnsiD· 2 shared Nicole M. VerrillsiD· 2 shared Sumit SahniiD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Daniel TillettORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

(E,E)-bisantrene suppresses MYC expression and displays anti-leukemic activity in acute myeloid leukemia

Heather C. Murray, Kasey Miller, Joshua S. Brzozowski, Dylan J. Kiltschewskij, Ishani Roy, Nikita Panicker, Ameha Seyoum Woldu, Benjamin J. Buckley, Marinella Messina, Chelsea Penney, Peter Cuthbertson, Sumit Sahni, Daniel Tillett, Michael J. Kelso, Jonathan R. Sillar, , Nicole M. Verrills

This study evaluates (E,E)-bisantrene's anti-leukemic activity in AML by showing it suppresses MYC expression and induces apoptosis across multiple models.

bioRxiv · Sep 16, 2026 · PreprintCancer Biology

Bisantrene potentiates tyrosine kinase inhibitor activity in clear cell renal cell carcinoma

Joshua S. Brzozowski, Sumit Sahni, Heather C. Murray, Lauren F. Watt, Dylan J. Kiltschewskij, Murray J. Cairns, Marinella Messina, Daniel Tillett, Michael J. Kelso, Nicole M. Verrills

This study shows bisantrene enhances the effectiveness of tyrosine kinase inhibitors in ccRCC by sustaining AKT inhibition and overcoming TKI resistance.

bioRxiv · Jul 21, 2025 · PreprintCancer Biology